Ukraine

Переглянути українською мовою

For more than 25 years we have provided Ukrainian patients with high-quality medicines and today employ over 200 people across all regions of Ukraine. Currently, GSK operates in Ukraine as GlaxoSmithKline Pharmaceuticals Ukraine LLC.

We actively implement the principles of transparency, integrity, respect, and patient focus. Our mission and values are always at the heart of everything we do for patients, healthcare professionals (HCPs), society, and our employees.

GSK response to the situation in Ukraine

Alongside the global community, we share deep concern about the tragic events happening in Ukraine. We are taking actions guided by our purpose, and as a company dedicated to health and care for people and patients.

Our first priority is the safety, security and wellbeing of GSK people, wherever they are located. After this, our focus is to make sure our products reach the people who need them, including supporting humanitarian efforts in Ukraine and surrounding countries.

We condemn the fighting and the harm and suffering it’s causing to people in Ukraine and beyond. The actions taking place are in violent contradiction to our purpose, and unshakeable belief that all people should be treated with dignity, respect and humanity.

How we’re helping through humanitarian aid

We are providing targeted humanitarian support through long-term NGO partners who have teams on the ground in Ukraine and neighbouring countries. We’ll continue to respond as the situation evolves, guided by our humanitarian principles.

We want to make sure our products reach the people who need them and support humanitarian efforts in Ukraine where we can:

• GSK people around the world have donated over £326,307 to Save the Children and the Red Cross, an amount GSK has matched.
• GSK is providing targeted humanitarian support through long-term NGO partners who have teams on the ground in Ukraine and neighbouring countries. We’ll continue to respond as the situation evolves, guided by our humanitarian principles.
• We’ve donated £3.25 million to the Red Cross and Save the Children who are providing food, water, first aid, medicines, warm clothes and shelter for people in Ukraine and refugees at the border.
• We’ve also donated £1 million to Crown Agents (an NGO that has worked with the Ukrainian Ministry of Health for the past 20 years) to fund medical trauma kits. And we’re having urgent discussions with them on how we can continue to supply essential medicines into Ukraine
• We’ve donated £2 million via the Global Fund to help  maintain HIV and TB treatment, diagnostics, and Opioid substitution therapy for internally displaced persons and hard to reach communities, who are vulnerable to treatment interruption.
• Through ViiV Healthcare, we have donated more than 10,000 packs of anti-retroviral medicines to national HIV/AIDS programmes and NGO partners across 4 countries, to support people living with HIV in the region who have been impacted by the conflict. This includes a significant donation of paediatric Tivicay for children living with HIV in Ukraine, as well as donations to support continued access to HIV treatment for displaced people in neighbouring countries.
• ViiV Healthcare is also providing funding of more than £850,000 from Positive Action to 12 community-based organisations, supporting humanitarian response activities both within Ukraine and surrounding countries.
• We have donated over 600,000 units of medicine and consumer products, including antibiotics, asthma medicine, treatments for epilepsy patients and pain relief products, to the Ukrainian Ministry of Health and other local partners, either directly or through Direct Relief, our long term humanitarian product donation partner.

Our GSK teams in neighbouring countries have contributed an additional 23,000 packs of healthcare products and £100,000 in donations to local charities.

GSK in Russia

The situation in Russia is complex and rapidly changing, and we continue to keep our approach under review.

Our priorities are to support GSK people and access to medicines and vaccines.

We support global sanctions and comply with them fully. We have taken a precautionary approach to stop, to the fullest extent possible, any direct involvement and support to the Russian government and military.

In line with our purpose to support people’s health, regardless of race, sex, nationality, ethnicity, language or religion, we believe everyone has the right to access healthcare and, as an innovator and supplier of needed medicines and vaccines, we have a responsibility to make them available while we can.

We continue to supply medicines and vaccines to Russia. Where we experience challenges delivering them, we will prioritise supply of products that are essential for people’s health (always in compliance with sanctions). This prioritisation will take into account medical criticality, patient need and availability of alternatives.

We have stopped promotional activities in Russia and any profits we make from our operations in Russia in the interim will be used to support humanitarian relief efforts.

We will not start any new clinical trials and are not enrolling new patients into existing clinical trials.

Contacts

Careers

Search for jobs in Ukraine

Data transparency

GSK fully supports the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code on the disclosure of individual transfer of value from pharmaceutical companies to healthcare professionals and healthcare organisations. We believe that it helps to create a better understanding of how the pharmaceutical industry partners and collaborates with HCPs and HCOs, and so increase confidence in the way that industry and the healthcare professionals work together.

We publish disclosure reports in line with the EFPIA Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations.

Click here to see our disclosure report for Ukraine

Financial statements of GSK Ukraine 2021

The financial and management reports for the year 2021 of GlaxoSmithKline Pharmaceuticals Ukraine LLC can be downloaded and viewed below. Annual financial statements with an auditor's report are published to meet the requirements of paragraph 2 of Part 3 of Art. 14 and Item 12 Chapter V. of the Law of Ukraine "On Accounting and Financial Reporting in Ukraine" dated 16.07.1999 № 996-XIV.”

Education

We have implemented several research projects on epidemiology to address specific scientific gaps in respiratory medicine (prevalence of COPD, asthma, and allergic rhinitis), inflammation (prevalence, morbidity, and use of medical resources in systemic lupus erythematosus) and oncology (prevalence, morbidity and use of medical resources in chronic lymphocytic leukaemia) in favour of patients. All epidemiological data are published in reputable medical journals and have become the basis for further value activities in the respective countries.

An important part of the global community's fight against antimicrobial resistance is the GSK-initiated international Survey of Antibiotic Resistance (SOAR) in 2002 in the Middle East, Africa, Latin America, Asia-Pacific and the CIS which was joined by Ukraine in 2011. SOAR studies the susceptibility of major pathogens of community-acquired respiratory infections to antimicrobials and is an indispensable tool in regulating the use of antibiotics. These studies are used to develop and implement local protocols for antibacterial therapy of community-acquired infections of the upper and lower respiratory tract. Throughout the years of the SOAR study it has been a reliable source of quality and scientifically sound information on the level of antibiotic resistance in the region. It is also a unique international project in Ukraine.

In Ukraine, where vaccination coverage is extremely low, we pay special attention to informational and educational programmes about the value of vaccination by organising numerous training courses for healthcare professionals, parents, journalists, hosting large-scale events such as the annual Vaccine Summit.

Our medical staff provide a sustained scientific dialogue with healthcare experts, addressing the needs of the scientific community for new scientific data and reliable medical information on vaccination, respiratory and anti-infective medicine.

Please note that GSK Group of Companies is not responsible for the information posted on third party sites. The materials use illustrations that are hypothetical and do not suggest that the depicted models underwent medical interventions or suffered from diseases.

The webpage is intended for users who are in Ukraine.